MedTrace Logo

Effects of the COTID (Community Occupational Therapist in Dementia) Program and Usual Occupational Therapy Care on Recurrence of Falls at 12 Months in Elderly People With Neurocognitive Disorders Who Had Been Hospitalized for Falls, After Their Return Home

NCT06237218 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2026-01-14

No results posted yet for this study

Summary

This project will enable optimization of specific carried out by occupationist for older adults discharged from hospital for falls:

* on the environmental dimension at the participant's home
* on the involvement of the caregiver since they are also involved in the care of the patient
* on the recurrence of falls and rehospitalizations in order to improve the quality of life by reassuring the elderly person when traveling
* on limiting loss of autonomy and staying at home. The occupational therapist will entrust the caregiver with a support role. The participant will feel more involved in the participant's care (thus reducing the feeling of helplessness). His actions will allow him to strengthen his sense of competence and will prevent him from physical and psychological exhaustion.

Conditions

  • Nervous System Diseases

Interventions

BEHAVIORAL

COTID program

COTID is a support program for people with Alzheimer's disease, designed to help them remain at home, including their primary caregiver.

Sponsors & Collaborators

  • University Hospital, Limoges

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-29
Primary Completion
2026-08-08
Completion
2027-03-08

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06237218 on ClinicalTrials.gov